Theravance Biopharma, Inc. (NASDAQ:TBPH) Cut to Sell at ValuEngine
ValuEngine cut shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) from a hold rating to a sell rating in a research report released on Tuesday.
A number of other equities analysts have also recently commented on the company. BidaskClub upgraded Theravance Biopharma from a hold rating to a buy rating in a report on Saturday, June 24th. Cantor Fitzgerald started coverage on Theravance Biopharma in a report on Friday, June 16th. They set an overweight rating and a $55.00 target price for the company. Leerink Swann set a $47.00 target price on Theravance Biopharma and gave the company a buy rating in a report on Wednesday, May 10th. Finally, Needham & Company LLC raised their target price on Theravance Biopharma from $40.00 to $45.00 and gave the company a buy rating in a report on Thursday, May 11th. Four research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $41.13.
Theravance Biopharma (NASDAQ TBPH) traded down 0.53% during mid-day trading on Tuesday, hitting $29.86. The company had a trading volume of 281,447 shares. Theravance Biopharma has a 52-week low of $23.80 and a 52-week high of $43.44. The company has a 50-day moving average price of $38.34 and a 200 day moving average price of $35.70. The company’s market capitalization is $1.59 billion.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.14) by $0.13. The business had revenue of $3.09 million for the quarter, compared to analysts’ expectations of $5.07 million. Theravance Biopharma had a negative return on equity of 67.69% and a negative net margin of 641.67%. On average, analysts forecast that Theravance Biopharma will post ($4.61) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/04/theravance-biopharma-inc-nasdaqtbph-cut-to-sell-at-valuengine.html.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Theravance Biopharma by 117,412.4% in the first quarter. BlackRock Inc. now owns 3,512,445 shares of the biopharmaceutical company’s stock valued at $129,326,000 after buying an additional 3,509,456 shares during the last quarter. Norges Bank bought a new position in shares of Theravance Biopharma during the fourth quarter valued at about $27,631,000. MARSHALL WACE ASIA Ltd bought a new position in shares of Theravance Biopharma during the first quarter valued at about $21,862,000. Marshall Wace North America L.P. bought a new position in shares of Theravance Biopharma during the first quarter valued at about $21,862,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Theravance Biopharma by 341.2% in the first quarter. Goldman Sachs Group Inc. now owns 256,110 shares of the biopharmaceutical company’s stock valued at $9,430,000 after buying an additional 198,062 shares during the last quarter. Institutional investors own 84.32% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.